We suggest you to use analysis of Cadus fundamentals to see if markets are presently mispricing the company. We found twenty-five available fundamental indicators for Cadus Corporation which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all Cadus fundamentals including its EBITDA as well as the relationship between Cash Flow from Operations and Retained Earnings . Please also double-check Cadus Corporation Price to Earning to validate the company can sustain itself down the road.Use Cadus to enhance returns of your portfolios. The stock experiences moderate upward volatility. Check odds of Cadus to be traded at $1.606 in 30 days
Cadus Company SummaryCadus competes with Regeneron Pharmaceuticals, Alexion Pharmaceuticals, Seattle Genetics, Sage Therapeutics, and . Cadus Corp purchases individual homes or residential lots for renovation or construction, and resale. As of March 15, 2016, its properties included 12 residential properties in MiamiDade County, Florida and 1 property in East Hampton, New York. Cadus Corp was formerly known as Cadus Pharmaceutical Corporationration and changed its name to Cadus Corporationration in June 2003. Cadus Corporationration was founded in 1992 and is based in New York, New York.
Cadus Return On Asset vs Cash and Equivalents
Cadus Corporation is rated third overall in return on asset category among related companies. It is rated below average in cash and equivalents category among related companies .